Status:
COMPLETED
Prospective HIV Chemotherapy Cohort Study
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Imperial College Healthcare NHS Trust
Conditions:
HIV
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Human Immunodeficiency Virus (HIV) infection is very successfully treated with a type of therapy called Highly Active AntiRetroviral Therapy (HAART). Although HAART has made a great improvement to the...
Detailed Description
STUDY DESIGN This study will be performed at one investigational site in the UK. This is a single centre, prospective observational cohort study of HIV positive individuals on suppressive HAART with m...
Eligibility Criteria
Inclusion
- Aged ≥ 18 years and able to give written informed consent
- Be aware of their HIV status and the diagnosis of malignancy
- Have a plasma viral load of \< 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment
- Be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel
Exclusion
- Patients not receiving HAART
- A detectable (\>50 HIV-1 RNA copies/ml) HIV plasma viral load at screening
- Opportunistic infections
- Unable or unwilling to give informed consent
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01902693
Start Date
October 1 2013
End Date
May 1 2015
Last Update
October 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chelsea and Westminster Hospital NHS Foundation Trust
London, United Kingdom, SW10 9NH